2nd Annual Heart in Diabetes (HID)

2nd Annual Heart in Diabetes (HID) is organized by The Metabolic Institute of America (TMIOA) and will be held during Jul 13 - 15, 2018 at Loews Philadelphia Hotel, Philadelphia, Pennsylvania, United States of America.

The target audience for this medical event is Cardiologist, Endocrinologists, Nephrologists Diabetologists, Lipidologists Internists, Family Clinicians, and other clinicians who are interested in the Heart in Diabetes. This CME Conference has been approved for a maximum of 18.75 AMA PRA Category 1 Credits.

Conference Objectives:
Upon completion of this meeting, participants should be able to:
• Describe the relationship between diabetes, obesity, and the heart
• Explain the roles of diabetes and obesity in the development of kidney disease, retinopathy, CVD, and arrhythmia
• Provide comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia, and hyperglycemia
• Understand cardiovascular outcomes trials (CVOT) and the role of real-life big data in assessing management
• Evaluate antihyperglycemic CVOT results, specifically the use of SGLT2 inhibitors and GLP1 RAs to reduce cardiovascular morbidity and mortality in patients with T2D
• Understand CHF in diabetes to implement best practices for the management of CHF
• Evaluate the extent of vascular disease in diabetes and cardiometabolic syndrome
• Explain the role of lipids, in particular LDL-C and non-HDL-C, in the development of atherosclerosis
• Describe the role of PCSK9 in lipid homeostasis and the impact of monoclonal antibody therapy with PCSK9 inhibitors on cardiovascular disease
• Understand risk categories and determine appropriate targets of lipid-lowering therapy as outlined in the AACE 2017 Dyslipidemia Management Clinical Guidelines
• Appropriately diagnose and treat hypercoagulation and thrombosis as consequences of insulin resistance, inflammation, and diabetes
• Address the proper anticoagulation agents in the management of the high-risk patient
• Understand the combination treatments of CHF, hypertension, and lipid disorders
• Discuss the role of combination therapy in the management of obesity and diabetes with a focus on incretin- and SGLT2 inhibitor–based treatment

Additional details will be posted as soon as they are available.